Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption.

The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.

Inclusion Criteria:

• Confirmed diagnosis of medullary thyroid cancer
• Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
• No serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Exclusion Criteria:

• Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
• Any serious and/or unstable pre-existing medical disorders
• Patients who are currently receiving any other investigational drug.

Medullary thyroid cancer patients who are actively considering enrolling in an observational clinical study for said condition, but have not yet completed enrollment and randomization phases.